their continued care. Such patients may then not require be transferred to a different facility to continue their psychiatric treatment, involuntarily.

Ugash Subramaney
Division of Psychiatry, Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa
Email: ugashs@absamail.co.za

References

The Vienna School of Clinical Research (VSCR)

I need to share my experience of the above institution, which was introduced to me coincidentally during discussions with an official from a pharmaceutical company. I was offered a brochure of the School, visited its website, and the rest is history.

The VSCR, based in Vienna, Austria, is a non-profit educational organization dedicated to improve clinical research and the application of its outcomes to evidence-based health care. The School achieves this by offering continuing education to professionals and clinicians to ensure high scientific standards in the generation and interpretation of clinical trial data and their application to clinical practice. It offers scholarships to applicants from developing countries on a merit basis. These are sponsored by the city of Vienna, the Austrian Ministry of Education, Science and Culture as well as by other public and private organizations.

The School has fully-based its activities on academic grounds. Close partnerships have been established with a number of renowned universities in Europe, the Middle East, Africa and the Americas.

The educational programme consists of a range of courses, workshops and therapeutic area seminars tailored to physicians/investigators and other hospital- and industry-based personnel involved in clinical research. They range from 3 – 6 days in length, end with a multiple-choice examination and are acknowledged within national and international programmes for continuing education. Though all the courses can be booked individually, completing a predetermined number of courses and workshops can lead to the acquisition of a VSCR diploma (basic and advanced level) for certification of special experience in clinical research.

The School does have an admission criteria, a limit to the numbers admitted per module, selection criteria for scholarships, and accreditation processes. More information is available on the School’s website: www.vscr.at.

I have been fortunate to receive a scholarship from the School to do some courses in 2004/2005. I am following the Health Outcomes Research stream, and have so far done 2 of the 3 Modules required for the basic diploma. The last Module is coming up next September. I felt unfairly privileged when I realized I was not only the only African by race, but also the only delegate from the African continent. When I raised this concern I learned to my amazement that the School has not had applications from the African continent. Now judging from the number of clinical trials being done in this country, let alone the continent, I feel a responsibility to popularize this resource, which I think a lot of professionals in this country should benefit from.

Edith Madela-Mntla
Deputy Director, Directorate Mental Health and Substance Abuse, Pretoria, South Africa
email: madele@health.gov.za

Pfizer Laboratories Launches GEODON™

Pfizer Laboratories takes pleasure in announcing the launch of GEODON™, a new atypical antipsychotic for the treatment of schizophrenia.

GEODON™ has a unique combination of pharmacological activities, and demonstrates:
• Predictable efficacy against both positive and negative symptoms in schizophrenia.
• Improvement of cognitive dysfunction and affective symptoms
• Favourable tolerability and a healthy metabolic profile

Switching to GEODON™ from currently available antipsychotic agents results in improvements in both positive and negative symptoms as well as improvements in symptoms of social impairment and cognition. Switching to GEODON™ also results in a significant reduction in weight and lipid levels, two important tolerability concerns with antipsychotic therapy.

GEODON™ is available as GEODON® IM (ziprasidone mesylate) for intramuscular injection and in an oral formulation, GEODON® Capsules (ziprasidone HCl). The flexible dosage formulations, including 20 mg/ml IM injection and 20, 40, 60 and 80 mg capsules, facilitate the acute treatment of schizophrenia and the transition to long-term therapy whilst allowing a pharmacological continuum.

GEODON, IM for Injection and GEODON® Capsules are available through Kinesis Logistics.

References available on request
For further information regarding GEODON™, contact Karin Keenan, GEODON™ Brand Manager on Tel: 011-320 6000.